Cereno Scientific has been cleared to launch a Phase 1 clinical trial in Sweden to evaluate the pharmacological properties of CS014, its experimental oral treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The upcoming study in healthy volunteers was designed based on feedback from the U.S.